Neuronetics (NASDAQ: STIM) — Perfil da empresa, notícias e dados financeiros
Neuronetics develops therapies for psychiatric disorders, focusing on transcranial magnetic stimulation for depression.

Neuronetics
Neuronetics (NASDAQ:STIM) is a medical technology company focused on developing innovative therapies for psychiatric and neurological disorders, with a particular emphasis on major depressive disorder. Their cornerstone project revolves around the NeuroStar Advanced Therapy system, a non-invasive treatment which utilizes transcranial magnetic stimulation (TMS) to target key areas of the brain associated with mood regulation. This technology offers hope to patients who haven't responded well to traditional antidepressant medications. With a mission to transform lives by offering new avenues in neurohealth, Neuronetics is dedicated to advancing their research and making their treatments more accessible to those in need. Their objectives include expanding the clinical applications of their technology, increasing adoption by healthcare providers, and continuing to build evidence for the efficacy and safety of their treatments.
Resumo
Operações
Produtos e/ou serviços de Neuronetics
- NeuroStar Advanced Therapy System, a non-invasive treatment for depression using transcranial magnetic stimulation.
- TouchStar treatment protocol, designed for shorter and more efficient sessions for patients undergoing depression therapy.
- NeuroStar Practice Consultants offer practices expertise in integrating NeuroStar therapy into clinical settings.
- NeuroStar Reimbursement Support Service assists patients and providers with insurance and reimbursement issues for treatments.
- MyNeuroStar.com provides resources for patients and clinicians, including educational materials and treatment tracking tools.
- NeuroStar Connect, a cloud-based platform that facilitates remote monitoring and management of treatment sessions by clinicians.
equipe executiva do Neuronetics
- Daniel L. ReuversCEO, President & Director
- Nir NaorExecutive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer
- Robert GreeneSenior Vice President of Sales
- Cory S. AndersonExecutive Vice President & General Manager of Greenbrook
Últimas notícias sobre a Neuronetics
Principais indicadores financeiros
Resultados divulgados pela Neuronetics, em USD.
- Cap. de mercado
- 166,9 mi
- Receita (TTM)
- 155,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -19.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 149,2 mi | -31,4 mi | -39 mi | |
| 74,9 mi | -34,6 mi | -43,7 mi | |
| 71,3 mi | -30,6 mi | -30,2 mi | |
| 65,2 mi | -35,1 mi | -37,2 mi |